Form 4: Crinetics Pharmaceuticals Director Reports Stock Transaction

Sentiment:

Insider Transaction (Form 4)


Wendell Wierenga, a Director of Crinetics Pharmaceuticals, Inc., reported multiple transactions in common stock on September 1, 2026.

Summary

  • Disposition to the issuer: disposed of 116,146 Common Stock at $85.00 ($9,872,410) on September 1, 2026; holds 5,925 after (Direct).
  • Disposition to the issuer: disposed of 5,925 Common Stock at $85.00 ($503,625) on September 1, 2026 (Direct).
  • Disposition to the issuer: disposed of 12,500 Stock Option (Right to Buy) at $61.76 ($772,000) on September 1, 2026 (Direct).
  • Disposition to the issuer: disposed of 12,500 Stock Option (Right to Buy) at $61.77 ($772,125) on September 1, 2026 (Direct).
  • Disposition to the issuer: disposed of 17,500 Stock Option (Right to Buy) at $64.77 ($1,133,475) on September 1, 2026 (Direct).
  • Disposition to the issuer: disposed of 17,500 Stock Option (Right to Buy) at $66.71 ($1,167,425) on September 1, 2026 (Direct).
  • Disposition to the issuer: disposed of 17,500 Stock Option (Right to Buy) at $64.68 ($1,131,900) on September 1, 2026 (Direct).
  • Disposition to the issuer: disposed of 12,500 Stock Option (Right to Buy) at $40.29 ($503,625) on September 1, 2026 (Direct).
  • Disposition to the issuer: disposed of 10,350 Stock Option (Right to Buy) at $52.67 ($545,134) on September 1, 2026 (Direct).
  • Disposition to the issuer: disposed of 9,730 Stock Option (Right to Buy) at $49.13 ($478,035) on September 1, 2026 (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Wendell Wierenga — Director

DateTransactionSecuritySharesPriceValueHeld After
2026-09-01Disposition to the issuerCommon Stock116,146$85$9.9M5,925
2026-09-01Disposition to the issuerCommon Stock5,925$85$503.6K0
2026-09-01Disposition to the issuerStock Option (Right to Buy)12,500$62$772.0K0
2026-09-01Disposition to the issuerStock Option (Right to Buy)12,500$62$772.1K0
2026-09-01Disposition to the issuerStock Option (Right to Buy)17,500$65$1.1M0
2026-09-01Disposition to the issuerStock Option (Right to Buy)17,500$67$1.2M0
2026-09-01Disposition to the issuerStock Option (Right to Buy)17,500$65$1.1M0
2026-09-01Disposition to the issuerStock Option (Right to Buy)12,500$40$503.6K0
2026-09-01Disposition to the issuerStock Option (Right to Buy)10,350$53$545.1K0
2026-09-01Disposition to the issuerStock Option (Right to Buy)9,730$49$478.0K0

Key Dates

DateDescription
2026-09-01Disposition to the issuer (116,146 shares)
2026-09-01Disposition to the issuer (5,925 shares)
2026-09-01Disposition to the issuer (12,500 shares)
2026-09-01Disposition to the issuer (12,500 shares)
2026-09-01Disposition to the issuer (17,500 shares)
2026-09-01Disposition to the issuer (17,500 shares)
2026-09-01Disposition to the issuer (17,500 shares)
2026-09-01Disposition to the issuer (12,500 shares)
2026-09-01Disposition to the issuer (10,350 shares)
2026-09-01Disposition to the issuer (9,730 shares)

Keywords

insider transaction, Form 4, CRNX, Crinetics Pharmaceuticals, Inc., neutral, Wendell Wierenga

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.